-
Major pharmaceutical firms, including MSD and AstraZeneca, have announced significant cuts to UK investments, citing poor government support, undervaluation of medicines, and an uncompetitive environment. These decisions threaten the UK’s ambitions to be a global life sciences hub, with job losses and stalled projects. The government promises to act, but industry concerns persist.
-
The UK government faces mounting pressure to support its science and technology sectors. Reports highlight risks of losing investment and talent to the US and other countries, with calls for policy reforms to boost innovation, attract global talent, and lead in quantum and AI development.
-
The UK has announced plans to build its first small modular reactors (SMRs) at Wylfa, Anglesey, with a government investment of £2.5 billion. The project aims to support up to 3,000 jobs and supply power to three million homes by the mid-2030s. The decision has sparked controversy, notably from the US, which preferred a large-scale project by Westinghouse. The site’s selection reflects a strategic move to revive UK nuclear industry and boost energy security.